Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034

نویسندگان

  • Vincent Madison
  • Andrew J. Prongay
  • Zhuyan Guo
  • Nanhua Yao
  • John Pichardo
  • Thierry Fischmann
  • Corey Strickland
  • Joseph Myers Jr
  • Patricia C. Weber
  • Brian M. Beyer
  • Richard Ingram
  • Zhi Hong
  • Winifred W. Prosise
  • Lata Ramanathan
  • S. Shane Taremi
  • Taisa Yarosh-Tomaine
  • Rumin Zhang
  • Mary Senior
  • Rong-Sheng Yang
  • Bruce Malcolm
  • Ashok Arasappan
  • Frank Bennett
  • Stephane L. Bogen
  • Kevin Chen
  • Edwin Jao
  • Yi-Tsung Liu
  • Raymond G. Lovey
  • Anil K. Saksena
  • Srikanth Venkatraman
  • Viyyoor Girijavallabhan
  • F. George Njoroge
چکیده

The structures of both native and S139A holo-HCV NS3/4A protease domain were solved to high resolution. Subsequently, structures were determined for a series of ketoamide inhibitors in complex with the protease. The changes in the inhibitor potency were correlated with changes in the buried surface area upon binding the inhibitor to the active site. The largest contributions to the binding energy arise from the hydrophobic interactions of the P1 and P2 groups as they bind to the S1 and S2 pockets. This correlation of the changes in potency with increased buried surface area contributed directly to the design of a potent tripeptide inhibitor of the HCV NS3/4A protease, which is currently in clinical trials.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

الگوهای جدید درمانی برای عفونت ویروس هپاتیت C

Hepatitis C virus (HCV) infection has affected approximately 180 million people across the world. In most cases, HCV-infection remains chronic, which expose patients at high risk of cirrhosis and hepatocellular carcinoma. The rates of disease incidence and mortality diminish as a result of successful treatment of HCV infection. Until the recent years, despite the associated toxicities and l...

متن کامل

غربالگری بیوانفورماتیکی مهارکننده‌(های) پروتئاز NS3/4A ویروس هپاتیت سی از دو گیاه دارویی Cornus officinalis و Syzygium aromaticum

Background: The hepatitis C virus (HCV) infection is a major global health problem and one of the common causes of mortality worldwide. Therefore, currently many studies have been focused on introducing novel and effective anti HCV agents especially plant materials. Therefore, the study was aimed to screening novel HCV protease inhibitor(s) from two medicinal plants including Cornus officinalis...

متن کامل

Computational Study on the Inhibitor Binding Mode and Allosteric Regulation Mechanism in Hepatitis C Virus NS3/4A Protein

HCV NS3/4A protein is an attractive therapeutic target responsible for harboring serine protease and RNA helicase activities during the viral replication. Small molecules binding at the interface between the protease and helicase domains can stabilize the closed conformation of the protein and thus block the catalytic function of HCV NS3/4A protein via an allosteric regulation mechanism. But th...

متن کامل

Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.

The hepatitis C virus (HCV) nonstructural (NS)3-NS4A serine protease heterocomplex is a prime target for development of novel HCV therapies, due to its essential role in maturation of the viral polyprotein. While the mode of substrate/inhibitor recognition of the HCV NS3/NS4A serine protease has been extensively studied in vitro, important molecular aspects of the mechanism of action for this m...

متن کامل

Identification of Non-Macrocyclic Small Molecule Inhibitors against the NS3/4A Serine Protease of Hepatitis C Virus through in Silico Screening

Drug discovery and design for inhibition of the Hepatitis C Virus (HCV) NS3/4A serine protease is a major challenge. The broad, shallow, and generally featureless nature of the active site makes it a difficult target for "hit" selection especially using standard docking programs. There are several macrocyclic NS3/4A protease inhibitors that have been approved or are in clinical trials to treat ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 15  شماره 

صفحات  -

تاریخ انتشار 2008